SCM
YARW

Soleus Capital Management’s Yarrow Bioscience YARW Stock Holding History

Soleus Capital Management’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14,077
Closed -$1.64M – 100
2023
Q4 		$1.64M Buy
+14,077
New +$2.19M 0.18% 57

Other funds holding YARW

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM
EAM
Exome Asset Management New York $162M AUM 259.04% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Soleus Capital Management's YARW Position: Q1 2024 in Review

Soleus Capital Management sold out of Yarrow Bioscience (YARW) in Q1 2024, closing a stake of 14,077 shares — an estimated $1.64M sold.

Soleus Capital Management first reported a position in YARW in Q4 2023 and held it in 1 quarter. The position peaked at $1.64M in Q4 2023. 30 funds tracked by Wall St. Rank hold YARW as of Q1 2024.

  • Soleus Capital Management reported no remaining Yarrow Bioscience position as of Q1 2024 after selling out during the quarter.
  • Soleus Capital Management sold 14,077 Yarrow Bioscience shares in Q1 2024, an estimated $1.64M.
  • Soleus Capital Management first reported a position in Yarrow Bioscience in Q4 2023 and held it in 1 quarter.
  • Soleus Capital Management's Yarrow Bioscience position peaked at $1.64M in Q4 2023.
  • 30 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q1 2024.

Based on Soleus Capital Management's 13F filing for Q1 2024, filed 15 May 2024.